1
|
Dang VQ, Vuong LN, Ho TM, Ha AN, Nguyen QN, Truong BT, Pham QT, Wang R, Norman RJ, Mol BW. The effectiveness of ICSI versus conventional IVF in couples with non-male factor infertility: study protocol for a randomised controlled trial. Hum Reprod Open 2019; 2019:hoz006. [PMID: 30937394 PMCID: PMC6436611 DOI: 10.1093/hropen/hoz006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 01/23/2019] [Accepted: 02/20/2019] [Indexed: 12/29/2022] Open
Abstract
Study questions Does ICSI result in a higher live birth rate as compared with conventional IVF in couples with non-male factor infertility? What is known already ICSI is primarily indicated for severe male factor infertility. While the use of ICSI for couples with non-male factor infertility has been increasing worldwide, this is not supported by data from randomised controlled trials. Evidence from non-randomised studies suggest no benefit from ICSI compared with conventional IVF in non-male factor infertility, if not a harm. Study design, size, duration This randomised, open-label, multi-centre trial aims to compare the effectiveness of one ICSI cycle and one conventional IVF cycle in infertile couples with non-male factor infertility. A total of 1064 couples will be randomly allocated to an ICSI group and a conventional IVF group. The estimated duration of the study is 30 months. Participants/materials, setting, methods Eligible couples are those whose husbands’ total sperm count and motility are normal, have undergone ≤2 previous IVF/ICSI attempts, use antagonist protocol for ovarian stimulation, agree to have ≤2 embryos transferred and are not participating in another IVF study at the same time. Women undergoing IVM cycles, using frozen semen or having a poor fertilisation (≤25%) in previous cycle will not be eligible. Couples will be randomised to undergo ICSI or conventional IVF (1:1) with ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle as the primary endpoint. All analyses will be conducted on an intention-to-treat basis. Effect sizes will be summarised as relative risk (RR), with precision evaluated by 95% CIs. STUDY FUNDING/COMPETING INTEREST(S) All authors declare having no conflict of interests with regards to this trial. This work was supported by a grant from MSD [MISP #57508]. Trial registration number NCT03428919. Trial registration date 8 February 2018. DATE OF FIRST PATIENT’S ENROLMENT 16 March 2018.
Collapse
Affiliation(s)
- V Q Dang
- IVFMD, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam.,HOPE Research Center, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam
| | - L N Vuong
- HOPE Research Center, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam.,Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at Ho Chi Minh City, 217 Hong Bang, District 5, Ho Chi Minh City, Vietnam
| | - T M Ho
- HOPE Research Center, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam.,IVFAS, An Sinh Hospital, 10 Tran Huy Lieu, Phu Nhuan District, Ho Chi Minh City, Vietnam
| | - A N Ha
- IVFMD, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam
| | - Q N Nguyen
- IVFMD, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam
| | - B T Truong
- IVFAS, An Sinh Hospital, 10 Tran Huy Lieu, Phu Nhuan District, Ho Chi Minh City, Vietnam
| | - Q T Pham
- IVFMD, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam.,HOPE Research Center, My Duc Hospital, 4 Nui Thanh, Tan Binh District, Ho Chi Minh City, Vietnam
| | - R Wang
- Discipline of Obstetrics and Gynaecology, Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Ground Floor, 55 King William Road, North Adelaide SA 5006 Adelaide, Australia
| | - R J Norman
- Discipline of Obstetrics and Gynaecology, Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Ground Floor, 55 King William Road, North Adelaide SA 5006 Adelaide, Australia.,Fertility SA, 431 King William Street, South Australia 5000, Adelaide, Australia
| | - B W Mol
- Department of Obstetrics and Gynaecology, School of Medicine, Monash University, 246 Clayton Road, Clayton 3168, Victoria, Australia
| |
Collapse
|
2
|
Blankenstein F, Truong BT, Thomas A, Thieme N, Zachriat C. Predictability of magnetic susceptibility artifacts from metallic orthodontic appliances in magnetic resonance imaging. J Orofac Orthop 2014; 76:14-29. [PMID: 25420942 DOI: 10.1007/s00056-014-0258-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2013] [Accepted: 11/27/2013] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Orthodontic appliances are often prophylactically removed prior to MRI examinations, although they are sometimes left in situ (out of ignorance). Either way, there is a risk of adverse consequences for the patient, as removing the appliance may incur avoidable costs and extensive dental treatment, whereas leaving them in can cause artifacts that can significantly impair the diagnostic quality of MRI. The aim of this study was to measure the size of experimental artifacts created by orthodontic devices and to develop criteria using sound material-science research for making MRI more compatible, thereby supporting radiologists and orthodontists in their efforts. METHODS Sixteen orthodontic small-device and wire specimens made of different steel and titanium or CoCr alloys were placed in a chambered water-filled phantom for MRI. Each was subjected to spin-echo and gradient-echo sequences at 1.5 and 3 Tesla. RESULTS We observed that artifact formation depends on the material properties (specimen size, crystalline structure, manufacture-related processing) and on the specifications of the MRI system used (main field strength, sequence type). Our results varied considerably according to the steel grades. Artifact radii ranged from 14 mm (spin echo at 1.5 Tesla) to 51 mm (gradient echo at 3 Tesla). No artifacts occurred at 1.5 Tesla around the titanium and CoCr specimens; the same observation was made with one of the steel grades. CONCLUSION Artifact size cannot be predicted merely from the designation "steel". Nor did the crystalline structure of the baseline material from which a steel device had been produced have major implications for artifact size. Relevant, however, was the magnetic permeability (or susceptibility) of the final products, which is not disclosed by the manufacturers, and it cannot be measured on fixed intraoral appliances. Furthermore, the present investigation reveals that some steel devices can remain in situ without triggering adverse consequences.
Collapse
Affiliation(s)
- F Blankenstein
- Centrum für Zahn- Mund- und Kieferheilkunde, Abteilung für Zahnärztliche Prothetik, Alterszahnmedizin und Funktionslehre, Charité-Universitätsmedizin Berlin, Aßmannshauser Str. 4-6, 14197, Berlin, Deutschland,
| | | | | | | | | |
Collapse
|
3
|
Blaydes SM, Kogan SC, Truong BT, Gilbert DJ, Jenkins NA, Copeland NG, Largaespada DA, Brannan CI. Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia. J Virol 2001; 75:9427-34. [PMID: 11533205 PMCID: PMC114510 DOI: 10.1128/jvi.75.19.9427-9434.2001] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2001] [Accepted: 06/19/2001] [Indexed: 11/20/2022] Open
Abstract
Juvenile myelomonocytic leukemia (JMML) is a disease that occurs in young children and is associated with a high mortality rate. In most patients, JMML has a progressive course leading to death by virtue of infection, bleeding, or progression to acute myeloid leukemia (AML). As it is known that children with neurofibromatosis type 1 syndrome have a markedly increased risk of developing JMML, we have previously developed a mouse model of JMML through reconstitution of lethally irradiated mice with hematopoietic stem cells homozygous for a loss-of-function mutation in the Nf1 gene (D. L. Largaespada, C. I. Brannan, N. A. Jenkins, and N. G. Copeland, Nat. Genet. 12:137-143, 1996). In the course of these experiments, we found that all these genetically identical reconstituted mice developed a JMML-like disorder, but only a subset went on to develop more acute disease. This result strongly suggests that additional genetic lesions are responsible for disease progression to AML. Here, we describe the production of a unique tumor panel, created using the BXH-2 genetic background, for identification of these additional genetic lesions. Using this tumor panel, we have identified a locus, Epi1, which maps 30 to 40 kb downstream of the Myb gene and appears to be the most common site of somatic viral integration in BXH-2 mice. Our findings suggest that proviral integrations at Epi1 cooperate with loss of Nf1 to cause AML.
Collapse
Affiliation(s)
- S M Blaydes
- Department of Molecular Genetics and Microbiology, Center for Mammalian Genetics, University of Florida College of Medicine, Gainesville, Florida 32610, USA
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193:531-43. [PMID: 11181704 PMCID: PMC2195904 DOI: 10.1084/jem.193.4.531] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The promyelocytic leukemia retinoic acid receptor alpha (PMLRARalpha) chimeric protein is associated with acute promyelocytic leukemia (APL). PMLRARalpha transgenic mice develop leukemia only after several months, suggesting that PMLRARalpha does not by itself confer a fully malignant phenotype. Suppression of apoptosis can have a central role in tumorigenesis; therefore, we assessed whether BCL-2 influenced the ability of PMLRARalpha to initiate leukemia. Evaluation of preleukemic animals showed that whereas PMLRARalpha alone modestly altered neutrophil maturation, the combination of PMLRARalpha and BCL-2 caused a marked accumulation of immature myeloid cells in bone marrow. Leukemias developed more rapidly in mice coexpressing PMLRARalpha and BCL-2 than in mice expressing PMLRARalpha alone, and all mice expressing both transgenes succumbed to leukemia by 7 mo. Although both preleukemic, doubly transgenic mice and leukemic animals had abundant promyelocytes in the bone marrow, only leukemic mice exhibited thrombocytopenia and dissemination of immature cells. Recurrent gain of chromosomes 7, 8, 10, and 15 and recurrent loss of chromosome 2 were identified in the leukemias. These chromosomal changes may be responsible for the suppression of normal hematopoiesis and dissemination characteristic of the acute leukemias. Our results indicate that genetic changes that inhibit apoptosis can cooperate with PMLRARalpha to initiate APL.
Collapse
MESH Headings
- Animals
- Antigens, Differentiation/genetics
- Apoptosis/genetics
- Bone Marrow Cells/cytology
- Calcium-Binding Proteins/genetics
- Calgranulin A
- Cell Differentiation
- Cell Division
- Cell Transformation, Neoplastic
- Chromosome Aberrations
- Chromosome Disorders
- Hematopoietic Stem Cells
- Leukemia, Promyelocytic, Acute/etiology
- Leukemia, Promyelocytic, Acute/mortality
- Leukemia, Promyelocytic, Acute/pathology
- Leukopoiesis
- Mice
- Mice, Transgenic
- Myeloid Cells/cytology
- Neoplasm Proteins/metabolism
- Neutrophils/cytology
- Oncogene Proteins, Fusion/metabolism
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Recombinant Fusion Proteins/metabolism
Collapse
Affiliation(s)
- S C Kogan
- Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California 94143, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|